Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 1/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.38 |
| ▸ | FDPS | P14324 | 2/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5548998 | 0.83 | TAAR1 (0.47) | TERTTBXAS1ALOX15TAAR1FDPS | |
| SCHEMBL285224 | 0.79 | TERT (0.59) | TERTTBXAS1ALOX15TAAR1FDPS | |
| SCHEMBL8671012 | 0.79 | FDPS (0.47) | ALOX15FDPSCYP2D6CHRM2CHRM1 | |
| SCHEMBL11185497 | 0.71 | FDPS (0.33) | ALOX15FDPSCYP2D6CHRM2CHRM1 | |
| SCHEMBL4775873 | 0.71 | TAAR1 (0.44) | TERTTAAR1CYP2D6 | |
| SCHEMBL3431746 | 0.71 | TBXAS1 (0.66) | TERTTBXAS1ALOX15TAAR1FDPS | |
| SCHEMBL9777191 | 0.71 | TBXAS1 (0.60) | TERTTBXAS1ALOX15TAAR1FDPS | |
| SCHEMBL5760548 | 0.69 | CHRM2 (0.42) | ALOX15FDPSCYP2D6CHRM2CHRM1 | |
| SCHEMBL28062565 | 0.69 | TBXAS1 (0.69) | TERTTBXAS1ALOX15TAAR1FDPS | |
| SCHEMBL503743 | 0.69 | TBXAS1 (0.69) | TERTTBXAS1ALOX15TAAR1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0349922-A2 | Aminoalkylaminocarbonyl aminodiol amino acid derivatives as anti-hypertensive agents | G.D. Searle & Co. (US) | 1990-01-10 | — | — | EP | claimed |
| EP-1785134-A2 | Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging | ALTEON, INC. (US) | 2007-05-16 | — | — | EP | disclosed |
| US-20060014781-A1 | Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging | SYNVISTA THERAPEUTICS, INC. | 2006-01-19 | — | — | US | disclosed |
| US-6960605-B2 | Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging | ALTEON, INC. (US) | 2005-11-01 | — | — | US | disclosed |
| US-20020022622-A1 | Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging | SYNVISTA THERAPEUTICS, INC. | 2002-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022622-A1 | Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging | ABAT, NDUFAB1, HSPE1 | TERT 231/4885TBXAS1 1509/4885ALOX15 2420/4885 |
| US-20060014781-A1 | Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging | ABAT, HSPE1, TXN2 | TERT 121/4885TBXAS1 1913/4885ALOX15 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.